Anti-Epileptic Drug Levetiracetam Prevents Alzheimer's Amyloid-Beta Formation in Preclinical Study
A preclinical study shows that the anti-epileptic drug levetiracetam can prevent the formation of amyloid-beta 42 in neurons by modulating synaptic vesicle recycling. Analysis of patient records indicates a modest delay in cognitive decline among Alzheimer's patients taking the drug, suggesting potential for very early preventive use.